Screener
G&A at other companies
Segments
By product
Where this comes from
Reported directly by First Tracks Biotherapeutics Inc in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The source filing: First Tracks Biotherapeutics Inc’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 4:32 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-224190
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating expenses: | ||
| Research and development | $33,955 | $41,465 |
| General and administrative | 18,856 | 9,815 |
| Total operating expenses | 52,811 | 51,280 |
| Loss from operations | (52,811) | (51,280) |
| Other income (expense), net: | ||
| Interest income | 2,328 | 4,091 |
| Other expense, net | (1) | (7) |
Item 1. Combined Financial Statements.
FAQ
- What is First Tracks Biotherapeutics Inc's G&A?
- First Tracks Biotherapeutics Inc (TRAX) reported G&A of $18.86M in Q1 2026.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.
Ask your AI about First Tracks Biotherapeutics Inc's g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude